Jim Hatch is a Professor Emeritus of Finance at Richard Ivey School of Business. He received a B. Comm. from the University of Saskatchewan in 1964, an MBA from McMaster University in 1965, and a PhD from the University of Michigan in 1972. Currently he is teaching the core finance course in the ...
Jim Hatch is a Professor Emeritus of Finance at Richard Ivey School of Business. He received a B. Comm. from the University of Saskatchewan in 1964, an MBA from McMaster University in 1965, and a PhD from the University of Michigan in 1972. Currently he is teaching the core finance course in the MBA Program and an elective course in Health Sector Finance in the MBA Program. He is the leader of the annual tour of China by MBA students. In recent years he has received multiple awards for excellence in teaching.
Hatch has written many cases, largely in the areas of investments, financial management, entrepreneurial finance, health care and biotechnology. In addition, he has written a number of articles, books and monographs. These publications are primarily in the areas of investments, capital markets, growth companies and banking. He is on the Board of Directors of a venture capital fund, Board of the Centre for Studies in Family Medicine, Advisory Board and member of the Executive Committee of ICHIL, the Business Advisory Board of the Centre for Canadian Surgical Technologies and Advanced Robotics, member of the CIHR-STP Program Advisory Committee, Editorial Board of the Case Research Journal, serves on an ad hoc committee of the Canadian Institutes for Health Research, and is a judge for the annual Canadian American Business Council Achievement Award.
Jim Hatch's current interests are in the areas of entrepreneurial finance, commercialization of health related technology and China. In particular he is interested in the financial challenges faced by small and medium sized firms that are growing rapidly or aspire to grow rapidly credit decision making by banks challenges facing the health sector, the financing of early stage biotechnology companies, and the culture and economics of China.